NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Given Average Rating of “Moderate Buy” by Brokerages

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) has received an average recommendation of “Moderate Buy” from the five analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $8.50.

Several research analysts have recently weighed in on NRSN shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NeuroSense Therapeutics in a research note on Monday, December 29th. Roth Mkm began coverage on shares of NeuroSense Therapeutics in a research note on Tuesday, March 10th. They issued a “buy” rating and a $3.00 price target on the stock. D. Boral Capital restated a “buy” rating and set a $14.00 price objective on shares of NeuroSense Therapeutics in a research report on Wednesday, March 25th. Finally, Wall Street Zen raised shares of NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, January 3rd.

NeuroSense Therapeutics Stock Performance

Shares of NRSN stock opened at $0.83 on Friday. The company has a market capitalization of $27.02 million, a P/E ratio of -1.54 and a beta of 1.70. The business’s 50 day moving average is $0.87 and its two-hundred day moving average is $0.99. NeuroSense Therapeutics has a 12-month low of $0.63 and a 12-month high of $2.60.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of NRSN. Squarepoint Ops LLC boosted its holdings in NeuroSense Therapeutics by 91.0% in the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after buying an additional 45,450 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of NeuroSense Therapeutics during the second quarter valued at approximately $54,000. Two Sigma Investments LP purchased a new position in shares of NeuroSense Therapeutics in the third quarter valued at approximately $26,000. Finally, Yorkville Advisors Global LP purchased a new position in shares of NeuroSense Therapeutics in the fourth quarter valued at approximately $77,000. 1.04% of the stock is owned by hedge funds and other institutional investors.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.